Latest on Medically in Rheumatology
medwireNews from Springer Healthcare: Difficult-to-treat RA characteristics vary among rheumatologists
The perceived characteristics of difficult-to-treat rheumatoid arthritis (RA) vary widely among rheumatologists, and are often not addressed by current EULAR management recommendations, shows an Annals of Rheumatic Diseases report.
medwireNews from Springer Healthcare: Baricitinib step down feasibility demonstrated in RA-BEYOND
The majority of patients with rheumatoid arthritis (RA) who step down treatment with baricitinib from 4 to 2 mg/day maintain low disease activity (LDA) or remission at 48 weeks, shows an analysis of data from the RA-BEYOND trial.
medwireNews from Springer Healthcare: Tocilizumab not linked to elevated cardiovascular risk in RA patients
Patients with rheumatoid arthritis (RA) who are treated with tocilizumab have a similar cardiovascular (CV) risk profile to those taking most other biological DMARDs, results of a real-world study suggest.
medwireNews from Springer Healthcare: Disease activity, corticosteroid use linked to preterm delivery risk in women with RA
Study findings indicate that disease activity and corticosteroid use may contribute to the elevated risk of preterm delivery among pregnant women with rheumatoid arthritis (RA).
medwireNews from Springer Healthcare: Biologic treatment may reduce vascular risk in patients with inflammatory arthritis
Current use of biologic DMARDs is associated with a reduction in the risk of cardiovascular events among patients with inflammatory arthritis, suggests an analysis of the Australian Rheumatology Association Database (ARAD).
medwireNews from Springer Healthcare: TNF inhibitors unlikely to raise cancer recurrence risk in RA patients
Treatment with tumour necrosis factor (TNF) inhibitors is not associated with a significantly increased risk of recurrent cancer among patients with rheumatoid arthritis (RA), researchers report.
medwireNews from Springer Healthcare: Early disease activity may predict methotrexate response, radiographic progression in RA patients
Results of a post-hoc analysis suggest that high early disease activity is associated with poor response to methotrexate and the occurrence of radiographic progression among patients with rheumatoid arthritis (RA)
medwireNews from Springer Healthcare: Phase II results support further investigation of baricitinib for SLE
Phase II trial results suggest that adding the JAK inhibitor baricitinib to standard care may be beneficial for patients with systemic lupus erythematosus.
medwireNews from Springer Healthcare: Model developed to predict methotrexate nonresponse in RA patients
Researchers have a developed a model including clinical and psychosocial factors to predict which patients with rheumatoid arthritis (RA) are unlikely to respond to methotrexate treatment.
Rheumatology and Immunology
Pathophysiology of Rheumatoid Arthritis, Systemic Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Giant Cell Arteritis, Granulomatosis with Polyangiitis, Microscopic Polyangiitis, Lupus Nephritis, Systemic Sclerosis, Pemphigus Vulgaris
The role of interleukin 6 (IL-6) in autoimmune diseases
Autoimmune diseases are a heterogeneous group of incompletely understood disorders. The complex pathophysiology of these disorders is regulated in part by a network of different cytokines. In this video learn about the role of IL-6 in inflammation, and how it can contribute to Rheumatoid Arthritis and other Autoimmune diseases.
Giant Cell Arteritis – one disease, many perspectives
GCA is a disease that touches the lives of many people, in different ways. We invite you to gain insights from different individuals as they each share their perspective and personal experience of GCA.